Femasys Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $4.47 million, or $1.33 per share, compared to a net loss of $4.59 million, or $3.18 per share, in the same period last year. Total revenue for the quarter was $331,827, an 18.9% decrease from $409,268 in the prior year, primarily due to lower international sales of its FemVue product. For the first half of 2026, the company generated $756,716 in revenue, a slight increase of 0.8% from $750,532 in the first half of 2025.
Operating expenses for the second quarter rose to $5.26 million, up 28.1% from $4.10 million in the same quarter of 2025. This increase was driven by higher research and development costs, which surged by 37.6% to $1.95 million, as the company transitioned development products into inventory to support commercialization. Sales and marketing expenses also increased by 31.4% to $1.29 million, reflecting higher compensation and travel costs. General and administrative expenses rose by 19.5% to $1.93 million, attributed to increased professional fees and facility costs.
Femasys has made significant strategic moves, including the appointment of John Canning as Chief Operating Officer to enhance operational execution and support commercial growth. The company also announced a strategic partnership with AMI Technologies to commercialize its fertility portfolio in Israel and launched FemaSeed Complete, a comprehensive fertility solution for OB/GYNs. Additionally, Femasys received CE Mark approval for its FemHSG Catheter, complementing its FemVue product for in-office fertility evaluations.
As of June 30, 2026, Femasys had cash and cash equivalents of $1.44 million, a significant decrease from $9.27 million at the end of 2025. The company has incurred recurring losses, with an accumulated deficit of $149.45 million. However, it recently completed a private placement transaction that generated approximately $30 million in gross proceeds, which management believes will provide sufficient liquidity to fund operations for at least the next twelve months. The company continues to invest in the commercialization of its products and the clinical development of its U.S. product candidate, FemBloc, while anticipating ongoing operating losses.
About FEMASYS INC
Femasys Inc. develops women’s health solutions, including non-surgical permanent birth control, artificial insemination, and diagnostic devices. Its products serve infertility and contraception markets worldwide, offering minimally invasive, cost-effective alternatives to surgery and traditional treatments. With a strong patent portfolio and regulatory approvals, the company focuses on innovative, in-office medical devices that improve safety, accessibility, and patient satisfaction in reproductive health.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov